ETRM: EnteroMedics Inc. Twitter

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 17, 8:05 AM EnteroMedics (ETRM) rises 15% before the bell after saying it has concluded a pre-Premarket Approval (so you're saying its preliminary?) application meeting at which the FDA said that once the company's application for the Maestro Rechargeable System's VBLOC vagal blocking therapy is accepted, and once a detailed review of the data is validated, the company can "anticipate presenting the PMA before a future FDA Advisory panel." Parsing that language: ETRM plans to submit a PMA in Q2. (PR) Comment! [Healthcare, On the Move]
Wednesday, May 1, 7:55 AM EnteroMedics (ETRM): Q1 EPS of -$0.14 misses by $0.01. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, February 22, 12:53 PM Midday top 10 gainers: WBMD +25%. EDAP +24%. PSDV +24%. ARUN +22%. BLOX +17%. SSTK +16%. FIRE +15%. B +15%. AVG +12%. RKUS +12%.
Midday top 10 losers: ETRM -20%. MMSI -19%. WIFI -18%. FRO -14%. NVGN -12%. CBMX -12%. VOLC -11%. GMXR -16%. RCKY -11%. REED -11%. Comment! [On the Move]
Friday, February 22, 9:26 AM Weight-loss device maker EnteroMedics (ETRM) -19.5% premarket on plans for a $13M public offering of 13.77M common shares and warrants to purchase 5.5M shares. ETRM had ~41.7M shares outstanding as of Dec. 31. Comment! [Healthcare, Consumer, On the Move]
Friday, February 22, 9:10 AM Premarket gainers: WBMD +19%. ARUN +14%. FIRE +13%. JOEZ +11%. CYBX +8%. MRVL +5%. GLUU +5%. HPQ +5%.
Losers: ETRM -17%. RAX -6%. FRO -6%. Comment! [On the Move]
Wednesday, February 13, 6:28 PM EnteroMedics (ETRM): Q4 EPS of -$0.17 misses by $0.03. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, February 8, 1:00 PM Midday top 10 gainers: BDCO +32%. CZR +25%. ONCY +23%. LNKD +20%. SNCR +19%. GALT +13%. ZN +13%. FLT +12%. ZNGA +12%. ATVI +11%.
Midday top 10 losers: ETRM -55%. MSON -22%. GUID -21%. NUAN -19%. RVBD -18%. QKLS -16%. JE -14%. NSP -13%. STS -11%. SPWR -10%. Comment! [On the Move]
Thursday, February 7, 6:55 PM EnteroMedics (ETRM) tanks in after hours trading after its electric shock device for weight-loss failed to meet its key goal in clinical trials. The goal was to help patients lose 10% more of their excess weight than patients implanted with a nonworking, or "sham," device. The 10% threshold was agreed upon by the company to meet the FDA's request that the device show " super superiority." However, the company says it still plans to forge ahead with seeking regulatory approval. Shares -50% AH. 3 Comments [Healthcare, On the Move]
Friday, September 23, 2011, 10:31 AM EnteroMedics (ETRM -9.1%) is down after closing out its secondary offering of 8.8M common shares and 1.76M warrants. It will use the proceeds from the sale to help fund the development of its Maestro RC System, which is used in the treatment of obesity, diabetes and hypertension. Comment! [Healthcare, On the Move]

ETRM EnteroMedics Inc.

ETRM

EnteroMedics Inc.